Related Experiment Video

Updated: Nov 30, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.7K

Selective Antitumor Effect of Shikonin Derived DMAKO-20 on Melanoma through CYP1B1

Junqi Cui1, Xiaobo Zhou1, Jia Huang1

  • 1Shanghai Ninth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Center for Specialty Strategy Research of Shanghai Jiao Tong University China Hospital Development Institute, Shanghai 200011,China.

Current Cancer Drug Targets
|November 17, 2020
PubMed
Abstract

Insights

Cytochrome P450 1B1 (CYP1B1) is highly expressed in melanoma and activates the anticancer drug DMAKO-20. This targeted activation leads to selective killing of melanoma cells, offering a potential new treatment strategy for skin carcinoma.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Cytochrome P450 1B1 (CYP1B1) is a key enzyme in drug metabolism and a potential target for cancer chemotherapy.
  • Naphthoquinone oximes, such as DMAKO-20, are activated by CYP1B1, but their efficacy and mechanism in melanoma remain largely unexplored.
  • Understanding CYP1B1 expression in melanoma is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the expression levels of CYP1B1 in melanoma tissues and cell lines.
  • To elucidate the molecular mechanisms underlying the anticancer activity of DMAKO-20 in melanoma.
  • To determine if DMAKO-20's effects are mediated by CYP1B1.

Main Methods:

  • Immunohistochemical staining was used to assess CYP1B1 expression in melanoma patient specimens and B16/F10 cells.
  • In vitro assays, including cytotoxicity, cell migration, apoptosis, and immunoblotting, were employed to study DMAKO-20's effects.
  • Gene silencing (shRNA) was used to confirm the role of CYP1B1 in DMAKO-20's activity.

Main Results:

  • CYP1B1 was found to be highly expressed in melanoma tissues and B16/F10 cells, but not in normal tissues.
  • DMAKO-20 demonstrated potent and selective antiproliferative and antimigratory effects on B16/F10 melanoma cells.
  • DMAKO-20 induced apoptosis in melanoma cells by upregulating Bax and downregulating Bcl-2, a process dependent on CYP1B1-mediated activation.

Conclusions:

  • DMAKO-20 exhibits selective cytotoxicity against melanoma cells via CYP1B1-mediated metabolic activation.
  • The findings highlight the potential of DMAKO-20 as a lead compound for developing novel therapeutic agents against malignant skin carcinomas.
  • Targeting CYP1B1 offers a promising strategy for enhancing the efficacy of DMAKO-20 in melanoma treatment.
Keywords:
Skin carcinomachemotherapycytochrome P450melanomapProdrug.shikonin

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K